Prop 65 NRT litigation
This article was originally published in The Tan Sheet
Executive Summary
Plaintiff Paul Dowhal "is mistaken" in asserting that FDA has only rejected one Prop 65 warning for NRT products, according to a reply brief filed in California Supreme Court June 16. "FDA has prohibited use of any articulation of the message that [Prop 65] requires...because it has determined that the substance of this message conflicts with the FD&C Act's prohibition on misbranding and thwarts the objective of avoiding overwarning," the brief maintains. Filed on behalf of 10 NRT manufacturers, marketers and retailers, the filing also takes issue with Dowhal's contention the firms rely on informal FDA correspondence to support their opposition to a Prop 65 warning (1"The Tan Sheet" April 28, 2003, p. 9). Dowhal "ignores the fact that this correspondence includes five NDA approval letters," the reply brief notes...
You may also be interested in...
NRT Firms’ Deference To “Informal” FDA Letters In Prop 65 Case Improper
NRT firms' reliance on "unpublished, ad hoc" FDA statements to support their contention that a Proposition 65 warning on OTC smoking cessation products conflicts with federal law is improper, according to a brief filed in California Supreme Court April 15
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.